Overview
Employees
1-10
Persons 3
Mentions in press and media 22
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 18, 2023 | Investors prefer debt over equity (but not venture debt) | Jeremy Abelson Contributor Share on Twitter Jeremy Abelson is the founder and lead portfolio manager of Irving Investors. More posts by this contributor You’re not going to grow into your 2021 valuation Investors are sitting on mountains of... |
| Jan 13, 2023 | You’re not going to grow into your 2021 valuation | Jeremy Abelson Contributor Share on Twitter Jeremy Abelson is the founder and lead portfolio manager of Irving Investors. More posts by this contributor Investors are sitting on mountains of cash: Where will it be deployed? What am I worth ... |
| Oct 25, 2022 | Investors are sitting on mountains of cash: Where will it be deployed? | Jeremy Abelson Contributor Share on Twitter Jeremy Abelson is the founder and lead portfolio manager of Irving Investors. Combining his experience as an operator and institutional investor, Abelson runs Irving as a multistrategy platform ma... |
| Apr 19, 2022 | What am I worth now? | Jeremy Abelson Contributor Share on Twitter Jeremy Abelson is the founder and lead portfolio manager of Irving Investors. Combining his experience as an operator and institutional investor, Abelson runs Irving as a multi-strategy platform m... |
| Jan 24, 2022 | For the first time in 4 years, profitability beats growth | Jeremy Abelson Contributor Share on Twitter Jeremy Abelson is the founder and lead portfolio manager of Irving Investors. Combining his experience as an operator and institutional investor, Abelson runs Irving as a multi-strategy platform m... |
| Nov 19, 2020 | Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders | The drug works by inhibiting an enzyme called lysine-specific demethylase, or LSD1, which plays a role in the progression of the diseases for which bomedemstat is indicated The Food and Drug Administration has given bomedemstat breakthrough... |
| Oct 14, 2016 | While the IPO market roars back, venture remains leery | Ben Narasin Contributor Ben Narasin was an entrepreneur for 25 years, a seed investor for 8 and is now a VC as a General Partner at Canvas Ventures. More posts by this contributor While the IPO market roars back, venture remains leery The i... |
| Apr 10, 2016 | The crossover is (almost) over: Public-market investors bail on tech startups | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! Historically, mature private companies relied on ... |
| Apr 10, 2016 | The crossover is (almost) over: Public-market investors bail on tech startups | Historically, mature private companies relied on “growth” or late-stage venture firms for their last round, or rounds, before filing for IPO. That ecosystem has been disrupted over the last few years as large public market focused investors... |
Show more
Reviews 0
FAQ about Irving Investors
What has the press written about Irving Investors?
Parsers VC has collected 22 articles mentioning Irving Investors, among them “Investors prefer debt over equity (but not venture debt)” (Apr 18, 2023) and “You’re not going to grow into your 2021 valuation” (Jan 13, 2023).
Is Irving Investors still active?
Yes, Irving Investors is active; its latest activity on Parsers VC dates from Jul 11, 2026.